AI주식인사이트AI Stock Insight
C

싸이토젠

217330KOSDAQ자연과학 및 공학 연구개발업

46.0 / 100

Reference Date: 2026-04-13

Financial Score18.5 / 40
News Sentiment12.5 / 25
Momentum5.0 / 20
Disclosure10.0 / 15
AI Analysis: PBR is significantly undervalued vs. peers but the high debt ratio poses financial risk. Declined 14.9% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

CytoGen focuses on liquid biopsy platforms based on CTC (Circulating Tumor Cells) technology, offering services such as supporting anti-cancer drug development, precision medicine, and health supplement sales. Key business areas include companion diagnostics development with pharmaceutical companies, medical device distribution, and health supplement sales, while also expanding globally through research and international collaborations.

Number of Employees

39people

Average Salary

64.4M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 120.074.0Point
PBR
2.59Industry Average 3.825.5Point

Lower than industry avg (good)

ROE
-29.06Industry Average -32.113.5Point

Below industry avg

Debt Ratio
31.95Industry Average 7.520.0Point

4.2x industry avg (risky)

Trend 2023~20255.5 / 10 points
Revenue Growth Rate
3.0 / 3

Avg ▲190.7% (2-year basis)

Operating Profit Growth Rate
2.5 / 3

Avg ▲16.5% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -38.7% (improving, 3yr)

Detailed News Sentiment

1 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position3.0Point

52w lower range (24%)

Current 4,035Won52-week high 9,42052-week low 2,320
1-month return1.0Point

1m -14.87% (falling)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

6 totalPositive 0Neutral 6Negative 0
  • Neutral본점소재지변경2026-03-31
  • Neutral정기주주총회결과2026-03-31
  • Neutral[기재정정]주주총회소집공고2026-03-23
  • Neutral전환사채(해외전환사채포함)발행후만기전사채취득2026-03-20
  • Neutral감사보고서제출2026-03-20